title: Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium.
abstract: We have developed an ex vivo method for delivering genes to the synovial lining of joints and expressing them intra-articularly. The present studies were designed to determine whether transfer of a human interleukin-1 receptor antagonist protein (IRAP) gene by this method was able to antagonize the intra-articular actions of interleukin-1. Intra-articular injections of human recombinant interleukin-1 beta (hrIL-1 beta) into the knees of control rabbits provoked a marked leukocytic infiltrate into the joint space, severe synovial thickening and hypercellularity, and loss of proteoglycans from articular cartilage. Genetically modified knees contained several nanograms of human IRAP and inhibited each of these effects of IL-1 beta. These data demonstrate for the first time that delivery of an appropriate gene to joints can prevent intra-articular pathology. Such findings permit cautious optimism about the eventual development of a gene treatment for arthritis and other disorders of the joint.
authors.affiliation: Ferguson Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, PA 15261, USA.
authors.forename: G L
authors.initials: GL
authors.lastname: Hung
authors.forename: J
authors.initials: J
authors.lastname: Galea-Lauri
authors.forename: G M
authors.initials: GM
authors.lastname: Mueller
authors.forename: H I
authors.initials: HI
authors.lastname: Georgescu
authors.forename: L A
authors.initials: LA
authors.lastname: Larkin
authors.forename: M K
authors.initials: MK
authors.lastname: Suchanek
authors.forename: M H
authors.initials: MH
authors.lastname: Tindal
authors.forename: P D
authors.initials: PD
authors.lastname: Robbins
authors.forename: C H
authors.initials: CH
authors.lastname: Evans
mesh_terms: D000818:Animals; D001168:Arthritis / Q000628:therapy; D018076:DNA, Complementary / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007270:Injections, Intra-Articular; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D007592:Joint Diseases / Q000628:therapy; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D012190:Retroviridae / Q000235:genetics; D012795:Sialoglycoproteins / Q000235:genetics*; D013583:Synovial Membrane / Q000276:immunology* / Q000473:pathology
chemical_list: D018076:DNA, Complementary; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins